Tuning the Transdermal Delivery of Hydroquinone upon Formulation with Novel Permeation Enhancers
dc.contributor.author | Serrano, Dolores R. | |
dc.contributor.author | Gordo, María José | |
dc.contributor.author | Matji, Antonio | |
dc.contributor.author | González, Salvador | |
dc.contributor.author | Lalatsa, Aikaterini | |
dc.contributor.author | Torrado Durán, Juan José | |
dc.date.accessioned | 2023-06-17T12:40:33Z | |
dc.date.available | 2023-06-17T12:40:33Z | |
dc.date.issued | 2019-04-04 | |
dc.description.abstract | Hydroquinone (HQ) is an anti-hyperpigmentation agent with poor physicochemical stability. HQ formulations are currently elaborated by compounding in local pharmacies. Variability in the characteristics of HQ topical formulations can lead to remarkable di_erences in terms of their stability, e_cacy, and toxicity. Four di_erent semisolid O/Wformulations with 5% HQ were prepared using: (i) Beeler´s base plus antioxidants (F1), (ii) Beeler´s base and dimethyl isosorbide (DMI) as solubiliser (F2), (iii) olive oil and DMI (F3), and (iv) Nourivan®, a skin-moisturising and antioxidant base, along with DMI (F4). Amongst the four formulations, F3 showed the greatest physicochemical stability with less tendency to coalescence but with marked chromatic aberrations. An inverse correlation was established by multivariate analysis between the mean droplet size in volume and the steady-state flux, which explains why F3, with the smallest droplet size and the most hydrophobic excipients, exhibited the highest permeation across both types of membranes with enhancement ratios of 2.26 and 5.67-fold across Strat-M® and mouse skin, respectively, compared to F1. It is crucial to understand how the HQ is formulated, bearing in mind that the use of di_erent excipients can tune the transdermal delivery of HQ significantly. | |
dc.description.department | Depto. de Farmacia Galénica y Tecnología Alimentaria | |
dc.description.faculty | Fac. de Farmacia | |
dc.description.refereed | TRUE | |
dc.description.status | pub | |
dc.eprint.id | https://eprints.ucm.es/id/eprint/70234 | |
dc.identifier.doi | 10.3390/pharmaceutics11040167 | |
dc.identifier.issn | 1999-4923 | |
dc.identifier.officialurl | https://doi.org/10.3390/pharmaceutics11040167 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/12755 | |
dc.issue.number | 4 | |
dc.journal.title | Pharmaceutics | |
dc.language.iso | eng | |
dc.page.initial | 167 | |
dc.publisher | MDPI | |
dc.rights | Atribución 3.0 España | |
dc.rights.accessRights | open access | |
dc.rights.uri | https://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject.cdu | 615.4 | |
dc.subject.keyword | Hydroquinone | |
dc.subject.keyword | Transdermal delivery | |
dc.subject.keyword | Franz cells | |
dc.subject.keyword | Permeability enhancers | |
dc.subject.keyword | Stability | |
dc.subject.keyword | Multivariate analysis | |
dc.subject.ucm | Tecnología farmaceútica | |
dc.title | Tuning the Transdermal Delivery of Hydroquinone upon Formulation with Novel Permeation Enhancers | |
dc.type | journal article | |
dc.volume.number | 11 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | a577e97d-a6c8-4552-8c78-f35c42216b92 | |
relation.isAuthorOfPublication.latestForDiscovery | a577e97d-a6c8-4552-8c78-f35c42216b92 |
Download
Original bundle
1 - 1 of 1
Loading...
- Name:
- pharmaceutics-11-00167-v2.pdf
- Size:
- 4.19 MB
- Format:
- Adobe Portable Document Format